Have a feature idea you'd love to see implemented?
Let us know!
Price (delayed)
$330.65
Market cap
$23.99B
P/E Ratio
46.5
Dividend/share
$0.6
EPS
$7.11
Enterprise value
$23.85B
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe,
Highlights
The stock's price to earnings (P/E) is 3.1% less than its last 4 quarters average of 48.0 and 2.7% less than its 5-year quarterly average of 47.8
WST's EPS is down by 7% since the previous quarter but it is up by 2.2% year-on-year
West Pharmaceutical Services's quick ratio has decreased by 44% YoY and by 16% from the previous quarter
The net income has contracted by 8% from the previous quarter
Key stats
What are the main financial stats of WST
Market
Valuations
Earnings
Shares outstanding
72.54M
Market cap
$23.99B
Enterprise value
$23.85B
Price to book (P/B)
9.35
Price to sales (P/S)
8.39
EV/EBIT
37.6
EV/EBITDA
30.56
EV/Sales
8.29
Revenue
$2.88B
EBIT
$634.3M
EBITDA
$780.4M
Free cash flow
$357.1M
Per share
Balance sheet
Liquidity
EPS
$7.11
Free cash flow per share
$4.89
Book value per share
$35.37
Revenue per share
$39.41
TBVPS
$46.15
Total assets
$3.49B
Total liabilities
$912.6M
Debt
$310.7M
Equity
$2.58B
Working capital
$849.3M
Debt to equity
0.12
Current ratio
2.34
Quick ratio
1.46
Net debt/EBITDA
-0.17
Margins
Efficiency
Dividend
EBITDA margin
27.1%
Gross margin
35.7%
Net margin
18.2%
Operating margin
20.4%
Return on assets
14.3%
Return on equity
19.1%
Return on invested capital
25%
Return on capital employed
22.2%
Return on sales
22%
Dividend yield
0.18%
DPS
$0.6
Payout ratio
8.4%
WST stock price
How has the West Pharmaceutical Services stock price performed over time
Intraday
15.43%
1 week
14.55%
1 month
6.76%
1 year
-10.57%
YTD
-6.1%
QTD
10.16%
Financial performance
How have West Pharmaceutical Services's revenue and profit performed over time
Revenue
$2.88B
Gross profit
$1.03B
Operating income
$587.2M
Net income
$524.9M
Gross margin
35.7%
Net margin
18.2%
The operating margin has declined by 11% year-on-year and by 7% since the previous quarter
WST's operating income is down by 10% YoY and by 9% from the previous quarter
The net income has contracted by 8% from the previous quarter
West Pharmaceutical Services's gross margin has decreased by 6% YoY and by 4% from the previous quarter
Growth
What is West Pharmaceutical Services's growth rate over time
Valuation
What is West Pharmaceutical Services stock price valuation
P/E
46.5
P/B
9.35
P/S
8.39
EV/EBIT
37.6
EV/EBITDA
30.56
EV/Sales
8.29
WST's EPS is down by 7% since the previous quarter but it is up by 2.2% year-on-year
The stock's price to earnings (P/E) is 3.1% less than its last 4 quarters average of 48.0 and 2.7% less than its 5-year quarterly average of 47.8
The price to book (P/B) is 9% lower than the 5-year quarterly average of 10.3 and 3.6% lower than the last 4 quarters average of 9.7
WST's equity is down by 6% year-on-year and by 3.9% since the previous quarter
The P/S is 9% below the last 4 quarters average of 9.2 and 7% below the 5-year quarterly average of 9.0
Efficiency
How efficient is West Pharmaceutical Services business performance
WST's return on invested capital is down by 9% since the previous quarter and by 4.2% year-on-year
WST's return on sales is down by 7% since the previous quarter
The company's return on assets fell by 7% QoQ
West Pharmaceutical Services's ROE has decreased by 6% from the previous quarter
Dividends
What is WST's dividend history
DPS
$0.6
Dividend yield
0.18%
Payout ratio
8.4%
Recent dividends
Special dividends are included in TTM DPS and yield
Financial health
How did West Pharmaceutical Services financials performed over time
West Pharmaceutical Services's quick ratio has decreased by 44% YoY and by 16% from the previous quarter
West Pharmaceutical Services's current ratio has decreased by 36% YoY and by 10% QoQ
WST's debt is 88% smaller than its equity
The debt to equity has grown by 9% from the previous quarter and by 9% YoY
WST's equity is down by 6% year-on-year and by 3.9% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.